Eli Lilly's retatrutide compound mimics three hormones associated with hunger regulation. "Lilly Reports Positive Results in Next-Gen Obesity Drug Trial -- Update," at 8:27 a.m. ET on Dec. 11, ...

In this video, Matthew S. Davids, MD, spoke about the BRUIN-314 trial, one of the first head-to-head studies to compare pirtobrutinib, a noncovalent Bruton tyrosine kinase inhibitor, with ibrutinib, a ...

Eli Lilly and Company has delivered significant positive developments this week, though its shares experienced a minor pullback in Wednesday's trading sessio ...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

Combining elacestrant with targeted agents produced “clinically meaningful” outcomes for patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer who have received at least ...

Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

Meanwhile, the 25-milligram dose of Novo Nordisk's oral semaglutide helped patients lose up to 16.6% of their weight on ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Eli Lilly and Company (NYSE: LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...